Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$7.74 USD
-0.24 (-3.01%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $7.74 0.00 (0.00%) 7:14 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Voyager Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 250 | 41 | 37 | 171 | 104 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 250 | 41 | 37 | 171 | 104 |
Selling & Adminstrative & Depr. & Amort Expenses | 128 | 92 | 111 | 144 | 156 |
Income After Depreciation & Amortization | 122 | -51 | -74 | 27 | -52 |
Non-Operating Income | 12 | 4 | 2 | 9 | 8 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 134 | -46 | -71 | 37 | -44 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 132 | -46 | -71 | 37 | -44 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 132 | -46 | -71 | 37 | -44 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 123 | -45 | -68 | 31 | -53 |
Depreciation & Amortization (Cash Flow) | 1 | 6 | 6 | 4 | -1 |
Income After Depreciation & Amortization | 122 | -51 | -74 | 27 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.57 | 38.36 | 37.67 | 37.35 | 35.90 |
Diluted EPS Before Non-Recurring Items | 2.97 | -1.21 | -1.89 | 0.98 | -1.21 |
Diluted Net EPS (GAAP) | 2.97 | -1.21 | -1.89 | 0.98 | -1.21 |
Fiscal Year end for Voyager Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 90.06 | 4.61 | 4.85 | 150.48 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 90.06 | 4.61 | 4.85 | 150.48 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 36.00 | 34.12 | 30.28 | 27.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 54.06 | -29.51 | -25.43 | 122.88 |
Non-Operating Income | NA | 3.15 | 3.43 | 3.28 | 1.86 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 57.22 | -26.08 | -22.15 | 124.75 |
Income Taxes | NA | 0.82 | -0.18 | 0.06 | 0.70 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 56.40 | -25.90 | -22.21 | 124.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 56.40 | -25.90 | -22.21 | 124.04 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 45.08 | 43.87 | 43.52 | 42.16 |
Diluted EPS Before Non-Recurring Items | NA | 1.25 | -0.59 | -0.51 | 2.94 |
Diluted Net EPS (GAAP) | NA | 1.13 | -0.59 | -0.51 | 2.94 |